20s Proteasome-Pipeline Review, H1 2016: KenResearch.com 20s Proteasome-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ’20s Proteasome-Pipeline Review, H1 2016′, provides in depth analysis on 20s Proteasome targeted pipeline therapeutics. The report provides comprehensive information on the 20s Proteasome , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.… Read More »
P-Selectin Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P-Pipeline Review, H1 2016: KenResearch.com P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein or CD62P)-Pipeline Review, H1 2016’, provides in depth analysis on P-Selectin (Granule Membrane Protein 140 or Platelet Activation Dependent Granule-External Membrane Protein… Read More »
Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2-Pipeline Review, H1 2016 Granulocyte Macrophage Colony Stimulating Factor GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2-Pipeline Review, H1 2016: KenResearch.com Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)-Pipeline Review, H1 2016’, provides in depth analysis on Granulocyte Macrophage Colony Stimulating… Read More »
Glycogen Synthase Kinase 3 Beta GSK-3 Beta or EC 2.7.11.26-Pipeline Review, H1 2016: KenResearch.com Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26)-Pipeline Review, H1 2016’, provides in depth analysis on Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) targeted pipeline therapeutics. The report provides comprehensive information on the… Read More »
Receptor Tyrosine Protein Kinase ERBB 4 Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1-Pipeline Review, H1 2016: KenResearch.com Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein… Read More »
Coagulation Factor XI Plasma Thromboplastin Antecedent or EC 3.4.21.27-Pipeline Review, H1 2016: KenResearch.com Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)-Pipeline Review, H1 2016’, provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted pipeline therapeutics. The report provides comprehensive information on the Coagulation Factor XI… Read More »
Proprotein Convertase Subtilisin/Kexin Type 9 Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.-Pipeline Review, H1 2016: KenResearch.com Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)-Pipeline Review, H1 2016’, provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type… Read More »
Programmed Cell Death 1 Ligand 1 PD-L1 or B7 Homolog 1 or B7-H1 or CD274-Pipeline Review, H1 2016: KenResearch.com Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274)-Pipeline Review, H1 2016’, provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog… Read More »
Global Urological Cancer Market to 2022-Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics: KenResearch.com Global Urological Cancer Market to 2022-Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics Summary Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer-the key indications covered in this report-accounting for the majority of that figure. Urological cancers… Read More »
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)-Pipeline Review, H1 2016: KenResearch.com Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)-Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)-Pipeline Review, H1 2016’, provides in depth analysis on Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted pipeline therapeutics. The… Read More »
